Alzheimer’s Disease Therapeutics Global Industry Sales, Supply, Demand and Consumption 2019 and Forecast to 2023

Jan 10, 2019

Wiseguyreports.Com Added New Market Research Report On -“Alzheimer’s Disease Therapeutics Market 2019 Key Players, Applications and Future Demand Forecast to 2023 ”.

Pune, India - January 10, 2019 /MarketersMedia/ —

Global Alzheimer's Disease Therapeutics Market

WiseGuyRerports.com Presents “Global Alzheimer's Disease Therapeutics and Diagnostics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database. The Report Contain 130 Pages With Detailed Analysis.

Description

Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.

Scope of the Report: 
This report focuses on the Alzheimer's Disease Therapeutics and Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. 

 

Get sample Report @ https://www.wiseguyreports.com/sample-request/3492293-global-alzheimer-s-disease-therapeutics-and-diagnostics-market

 

The worldwide market for Alzheimer's Disease Therapeutics and Diagnostics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers 
Namenda 
Aricept 
Exelon 
Solanezumab 
Gantenerumab 
Verubecestat 
Pfizer 
Eisai 
Actavis 
Lundbeck 
Daiichi Sankyo 
Novartis 
TauRx

Market Segment by Regions, regional analysis covers 
North America (United States, Canada and Mexico) 
Europe (Germany, France, UK, Russia and Italy) 
Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 
South America (Brazil, Argentina, Colombia etc.) 
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers 
Biomarkers 
Cholinesterase inhibitors 
NMDA receptor antagonists 
Brain imaging 
Blood tests

Market Segment by Applications, can be divided into 
Drugs Market 
Diagnostics Market

 

Complete Report Details @ https://www.wiseguyreports.com/reports/3492293-global-alzheimer-s-disease-therapeutics-and-diagnostics-market

 

Table of Contents -Major Key Points

1 Market Overview 
1 Market Overview 
1.1 Alzheimer's Disease Therapeutics and Diagnostics Introduction 
1.2 Market Analysis by Type 
1.2.1 Biomarkers 
1.2.2 Cholinesterase inhibitors 
1.2.3 NMDA receptor antagonists 
1.2.4 Brain imaging 
1.2.5 Blood tests 
1.3 Market Analysis by Applications 
1.3.1 Drugs Market 
1.3.2 Diagnostics Market 
1.4 Market Analysis by Regions 
1.4.1 North America (United States, Canada and Mexico) 
1.4.1.1 United States Market States and Outlook (2013-2023) 
1.4.1.2 Canada Market States and Outlook (2013-2023) 
1.4.1.3 Mexico Market States and Outlook (2013-2023) 
1.4.2 Europe (Germany, France, UK, Russia and Italy) 
1.4.2.1 Germany Market States and Outlook (2013-2023) 
1.4.2.2 France Market States and Outlook (2013-2023) 
1.4.2.3 UK Market States and Outlook (2013-2023) 
1.4.2.4 Russia Market States and Outlook (2013-2023) 
1.4.2.5 Italy Market States and Outlook (2013-2023) 
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 
1.4.3.1 China Market States and Outlook (2013-2023) 
1.4.3.2 Japan Market States and Outlook (2013-2023) 
1.4.3.3 Korea Market States and Outlook (2013-2023) 
1.4.3.4 India Market States and Outlook (2013-2023) 
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023) 
1.4.4 South America, Middle East and Africa 
1.4.4.1 Brazil Market States and Outlook (2013-2023) 
1.4.4.2 Egypt Market States and Outlook (2013-2023) 
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023) 
1.4.4.4 South Africa Market States and Outlook (2013-2023) 
1.4.4.5 Nigeria Market States and Outlook (2013-2023) 
1.5 Market Dynamics 
1.5.1 Market Opportunities 
1.5.2 Market Risk 
1.5.3 Market Driving Force 

2 Manufacturers Profiles 
2.1 Namenda 
2.1.1 Business Overview 
2.1.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications 
2.1.2.1 Product A 
2.1.2.2 Product B 
2.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 
2.2 Aricept 
2.2.1 Business Overview 
2.2.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications 
2.2.2.1 Product A 
2.2.2.2 Product B 
2.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 
2.3 Exelon 
2.3.1 Business Overview 
2.3.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications 
2.3.2.1 Product A 
2.3.2.2 Product B 
2.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 
2.4 Solanezumab 
2.4.1 Business Overview 
2.4.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications 
2.4.2.1 Product A 
2.4.2.2 Product B 
2.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 
2.5 Gantenerumab 
2.5.1 Business Overview 
2.5.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications 
2.5.2.1 Product A 
2.5.2.2 Product B 
2.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 
2.6 Verubecestat 
2.6.1 Business Overview 
2.6.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications 
2.6.2.1 Product A 
2.6.2.2 Product B 
2.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 

……..CONTINUED

 

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseguyReports
Address: Office No. 528/524, Amanora Chambers, Magarpatta Road, Hadapsar Pune, Maharashtra 411028
Phone: +44 208 133 9349
Website: http://www.wiseguyreports.com

Source URL: https://marketersmedia.com/alzheimers-disease-therapeutics-global-industry-sales-supply-demand-and-consumption-2019-and-forecast-to-2023/468396

Source: MarketersMedia

Release ID: 468396

More News

article.head.headline
Oct 10, 2026
Jessica Biel's pre-teen son hated her plunging movie dress

Jessica Biel takes on an action-packed role in Matchbox: The Movie, and also has the opportunity to show off her incredible figure in one particular scene.

article.head.headline
Oct 10, 2026
Screen Queen TV reviews: Dustfall, Celebrity Traitors, The State Of Man, The Diplomat and Chrystal Lake

I don’t say this lightly: these are two of the very best shows of the past decade — this drama, which packs one heck of a punch, is right up there with them.

article.head.headline
Oct 10, 2026
Michael Douglas 'not proud' of how he avoided being drafted during Vietnam War

Michael Douglas made the admission in his new memoir, titled One Helluva Ride.

article.head.headline
Oct 10, 2026
Ed Sheeran's cousin keen to 'hug and make up' after bitter feud

Jethro Sheeran insisted he would be "more than happy to move on" and apologise if Ed does the same.

article.head.headline
Oct 10, 2026
Sienna Miller is a 'bohemian' breastfeeder

Sienna Miller has urged people to "free the nipple" while defending her "bohemian" approach to breastfeeding.

article.head.headline
Oct 10, 2026
Catherine Zeta-Jones airs Welsh accent in Kill Jackie

After decades in show business, Catherine Zeta-Jones is finally playing a Welsh character, complete with her own natural accent, for the first time.

article.head.headline
Oct 10, 2026
Nickelback announces Australian return for October 2027 with Everything Under The Sun Tour

One of Canada’s most polarising rock bands will treat their Aussie fans to a return trip next year as Nickelback rolls out their 2027 Everything Under The Sun Tour.

article.head.headline
Oct 10, 2026
George Clooney breaks silence on Presley Gerber's 'devastating' death

George Clooney says Presley Gerber’s death is “the worst thing that could ever happen with family".

article.head.headline
Oct 10, 2026
Yorke had 'confidence crash' after Radiohead reunion

Radiohead frontman Thom Yorke has admitted he suffered a "crash" in "self-confidence" after the band's 2025 reunion tour and it took him "months" to recover.

article.head.headline
Oct 10, 2026
Sadie Sink to star in Emma Cline's The Guest

Sadie Sink is in talks to star in an adaptation of Emma Cline’s The Guest, from writer-director Lorene Scafaria.

article.head.headline
Oct 10, 2026
Susan Boyle's life story to be told in new documentary

There's Only One Susan Boyle will feature an interview with the singer along with insights from her friends and family.

article.head.headline
Oct 10, 2026
Matty J admits shame over looking up to Sam Wood following DV assault charges

Bachelor star Matty J has dropped a bombshell on the man he once called his “benchmark” for success, after Sam Wood was hit with domestic violence charges.


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

E-Stardom

E-Stardom is the exclusive online news network for breaking entertainment news. We bring to you the premium coverage and fashion tips to your favorite celebrity style. Get your daily celebrity news fix only here in E-Stardom.